×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:SYBX

Synlogic (SYBX) Stock Forecast, Price & News

$1.10
+0.01 (+0.92%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.07
$1.14
50-Day Range
$1.07
$2.55
52-Week Range
$1.02
$4.54
Volume
98,657 shs
Average Volume
124,380 shs
Market Capitalization
$77.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.56
30 days | 90 days | 365 days | Advanced Chart
Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

Synlogic logo

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Headlines

Synlogic (NASDAQ:SYBX) Price Target Cut to $6.00
Synlogic Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYBX
Employees
84
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.75 million
Book Value
$1.88 per share

Profitability

Net Income
$-60.56 million
Net Margins
-3,067.42%
Pretax Margin
-3,067.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
57,641,000
Market Cap
$77.28 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/27/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.59 out of 5 stars

Medical Sector

92nd out of 1,424 stocks

Pharmaceutical Preparations Industry

35th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Synlogic had a negative net margin of 3,067.42% and a negative trailing twelve-month return on equity of 43.07%. During the same quarter in the previous year, the company posted ($0.36) EPS.
View Synlogic's earnings history
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

5 equities research analysts have issued 1-year target prices for Synlogic's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Synlogic's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 627.3% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?
Synlogic's management team includes the following people:
  • Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc, Pres, CEO & Director (Age 46, Pay $891.42k)
  • Mr. Antoine Awad, Chief Operating Officer (Age 42, Pay $572.92k)
  • Dr. Timothy K. Lu M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 41)
  • Dr. James J. Collins Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 56)
  • Mr. Michael Jensen, Chief Financial Officer
  • Dr. David L. Hava Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
  • Mr. Daniel Rosan, Sr. VP & Head of Investor Relations
  • Mr. Brendan St. Amant, Head of Legal
  • Mr. Adam Thomas, Chief People Officer & Sec.
What other stocks do shareholders of Synlogic own?
What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by many different retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (3.69%), Vanguard Group Inc. (3.22%), Dimensional Fund Advisors LP (0.85%), Harbor Capital Advisors Inc. (0.51%), State Street Corp (0.18%) and Northern Trust Corp (0.13%). Company insiders that own Synlogic stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen.
View institutional ownership trends for Synlogic
.

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Harbor Capital Advisors Inc., Acadian Asset Management LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., and Simplex Trading LLC. Company insiders that have sold Synlogic company stock in the last year include Antoine Awad, and Aoife Brennan.
View insider buying and selling activity for Synlogic
or view top insider-selling stocks.

Which major investors are buying Synlogic stock?

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., State Street Corp, UBS Group AG, Ensign Peak Advisors Inc, UMA Financial Services Inc., Northern Trust Corp, and Group One Trading L.P..
View insider buying and selling activity for Synlogic
or or view top insider-buying stocks.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $1.10.

How much money does Synlogic make?

Synlogic has a market capitalization of $77.28 million and generates $1.75 million in revenue each year. The biotechnology company earns $-60.56 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 84 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at (617) 401-9975, via email at [email protected], or via fax at 512-681-5201.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.